Roivant Sciences ROIV 深 沪
已收盘 10-02 16:00:00 美东时间
35.72
+0.220
+0.62%
华盛通- 最 高36.00
- 今 开35.61
- 成交量 436.58万股
- 最 低 35.19
- 昨 收 35.50
- 总市值 258.01亿
- 52周最高 42.50
- 市盈率 静 --
- 换手率 0.60%
- 52周最低 15.99
- 委 比 97.34%
- 总股本 7.22亿
- 历史最高 42.50
- 量 比 0.76
- 振 幅 2.28%
- 历史最低 2.52
- 每 手 1
- 风险率 6.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a market capitalization of $25.77 billion. Buying $1000 In ROIV: If an investor had bought $1000 of ROIV sto...
10-02 07:15
Immunovant Ends Autoimmune Skin Disorder Program
Roivant Sciences Ltd. (NASDAQ:ROIV) announced that Immunovant Inc. (NASDAQ:IMVT) plans to halt the development of IMVT-1402 as a treatment for cutaneous lupus erythematosus (CLE). The decision follows recent proof-of-concept trial results that failed to reach statistical significance. Shares of both...
09-23 21:03
Roivant slips as Immunovant faces trial setback for cutaneous lupus therapy
Roivant (ROIV) traded lower in the premarket on Wednesday after its subsidiary Immunovant (IMVT) failed in a proof-of-concept trial for IMVT-1402, an experimental therapy for a skin-related autoimmune...
09-23 19:27
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51
Stifel analyst Alex Thompson initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $51.
09-17 18:24
美股周升幅榜 | 生物制药公司Roivant周升16.9%，二期试验数据积极；光通信概念股暴升！诺基亚周升11%
Qorvo抽升13.4%，与Skyworks价值220亿美元的合并料年底完成；生物制药公司Roivant周升16.9%，二期试验数据积极；光通信概念股暴升！诺基亚周升11%>>
09-12 10:24
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
美股牛股 | Roivant Sciences飙近19%， II期临床试验数据积极；软银劲升18%，宣布提前偿还259亿美元贷款；能源股走强，SEI升逾16%，SMR升逾15%
Roivant Sciences飙近19%， II期临床试验数据积极；软银劲升18%，宣布提前偿还259亿美元贷款；能源股走强，SEI升逾16%，SMR升逾15%>>
09-09 19:12
美股大行评级 | 多家大行齐上调Robinhood目标价！最高看至150美元；安进股价大跌后评级遭下调
今日重点评级关注：Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.3美元升至8.45美元；摩根大通：维持Vera Therapeutics"超配"评级，目标价从76美元升至83美元
09-09 15:36
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling around 450 points on Tuesday. Shares of Roivant Sciences Ltd (NASDAQ:ROIV) rose sharply during Tuesday’s session after the company shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension ass...
09-08 22:03
